Olangim tablets 10mg Agimexpharm treat schizophrenia (5 blisters x 10 tablets)

Risk of narrow -angle glaucom.

Precautions when using

Clinical improvement only appears after treatment from a few days to a few weeks. Need to monitor patients during this time.

Mental disorders are related to dementia and/or behavioral disorders: It is not recommended to use olanzapine for this group of objects because of increased death and risk of stroke.

Parkinson's disease: It is not recommended to use Planzapin in the treatment of mental disorders related to dopamine owner in Parkinson's patient. In clinical trials, worse jobs are Parkinson's symptoms and hallucinations that have been reported more commonly and more common than Placebo, and olanzapin is not more effective than Placebo in the treatment of neuropathy symptoms.

Malignant neuropular syndrome: is a life that threatens life related to the use of anti -psychotic drugs. The clinical manifestations of this syndrome are high fever, muscular, mental change, imbalance of autonomy nervous system (pulse or blood pressure, tachycardia, sweating and arrhythmia), accompanied by signs such as increased creatinine phosphokinase, myoglobin urine (Mechanical Prize), and acute kidney failure.

If a patient has signs and symptoms of a neuropular syndrome, or an unexplained fever is not accompanied by clinical manifestations of malignant neuroleptic syndrome, mental anti -dysplasia drugs (including olanzapine) must be stopped.

Hyperborn and diabetes: Hyperglycemia and/or make diabetes worse than diabetes, when it is related to a coma, coma has been reported in a rare report, including some deaths. In some cases, patients have previous weight gain, which can not be forecast.

Should follow the appropriate clinical monitoring according to the instructions for anti -psychotic drugs. Patients treated with any anti -dystreaking drugs, including olanzapine, should be monitored with signs and symptoms of hyperglycemia (such as thirsty, urinary, eating a lot and weakness) and patients with diabetes or having risk factors of diabetes should be monitored regularly with poor blood sugar control. Should monitor regular weight.

Lipid disorders: In a controlled clinical trial with a group of evidence, unwanted lipid disorders have been observed in patients treated with olanzapine. Lipid disorders should be appropriate clinical control, especially patients with lipid disorders and patients with risk factors for progression of lipid disorders. Patients treated with any anti -dystreaking drugs, including olanzapine, should be monitored lipid regularly under the instructions of the anti -neurological drug.

Neutral leukemia: Precautions for patients with low number of leukemia and/or neutrophils due to any cause, patients taking neutrophils that cause neutropenia, patients with a history of inhibition/bone marrow poisoning due to drugs, patients with bone marrow inhibitor in combination with radiation or chemotherapy and patients with acidic hypernagology or bone marrow hyperplasia. Neutral leukocytes have been reported as common when using Planzapin combination with Valproat and in patients with acidic leukemia or bone marrow hyperetopen.

Stop drugs: Very rare acute symptoms such as sweating, insomnia, tremor, anxiety, nausea or vomiting when stopping olanzapin suddenly.

Increased QT interval: It is necessary to be cautious when prescribing olanzapin along with the known drugs that work to extend the QT range, especially in the elderly, patients with congenital QT syndrome, congenital heart failure, heart hypertrophy, hypotension and hypoglycemia.

Vascular thrombosis: Very rare, the relationship between the occurrence of venous thrombosis and the use of planzapin has not been clearly proven. However, due to patients with schizophrenia often have risk factors for venous thrombosis, such as motionless patients, possible risk factors for venous thrombosis should be identified and prophetic evaluation.

Late dysplasia: The risk of late dysplasia increases in long -term use. Therefore, if there are signs of symptoms of late dysplasia appear in patients using planzapin, should consider reducing the dose or stopping the drug.

Seism: Olanzapin should be used with a history of convulsions or risk factors that lower the seizure threshold. Convulsions have been reported rare in patients treated with olanzapine. In most of these cases, there are reports on convulsions or risk factors.

Hemodynamic effects: olanzapine can cause vertical hypotension accompanied by dizziness, tachycardia and in several patients, unconscious, especially in the stage of determining the starting dose, possibly due to the influence of the alpha-1-adrenergic receptor resistance.

Suddenly due to heart disease: In the test report after the market, the deaths from heart disease have been reported in patients using Planzapin. In a rescue statistical survey, the risk of sudden death in patients treated with olanzapin is approximately twice in patients who do not use anti -neurological drugs. In the study, the risk of olanzapine is similar to that of non -typical anti -dysliths in an analysis.

Increased enaminase enamel: Be cautious in patients with signs and symptoms of liver failure, the previous patient has a limit on liver function and patients who are treating drugs that can toxic liver toxicity. Proposal periodic assessment of transaminase in patients with severe liver disease.

Regulating body temperature: The psychotropic drugs lose the ability to lower the body's body temperature. Be careful when prescribing Planzapin for patients who are in a state may increase body temperature as if they are trying to exertion, exposure to strong heat sources, taking cholinergic anti -drugs, or dehydration.

Difficulty swallowing: Loss of esophageal and respiratory movement is associated with the use of psychotic drugs. Inhalation pneumonia is a common cause of worse or fatal in Alzheimer patients. Olanzapin should be used with mental disorders in patients at risk of inhaling pneumonia.

suicide: The ability to commit suicide inherent in schizophrenia and bipolar disorder. Should closely monitor patients at high risk of suicide associated with drug treatment.

Anti -anti -anti -cholinergic activity: Be cautious in patients with benign prostatic hypertrophy, narrow -angle glaucoma or bowel history due to the anti -cholinergic effect of.

The effect on the central nervous system: Precautions when combining Planzapin with medications on central nervous and alcohol.

Increases the blood prolactin level in children and adolescents.

Lactose: Olangim's excipient component has lactose. Patients with Galactose intolerant, lactose deficiency or glucose-Galactose are not absorbed by this drug.

Seism: Olanzapin should be used with a history of convulsions or risk factors that lower the seizure threshold. Convulsions have been reported rare in patients treated with Planzapin. In most of these cases, there are reports on convulsions or risk factors.

Hemodynamic effects: olanzapine can cause vertical hypotension accompanied by dizziness, tachycardia and in several patients, unconscious, especially in the stage of determining the starting dose, possibly due to the influence of the alpha-1-adrenergic receptor resistance.

The ability to drive and operate machinery

Because olanzapine has the ability to reduce judgment, thought or motor skills, the drug also causes chicken sleep, dizziness, so the patient is careful while operating dangerous machines such as driving cars until it is sure that Olanzapin treatment does not cause side effects.

Pregnancy

There is no adequate test and strict control in pregnant women. Do not use olanzapin for pregnant women.

Breastfeeding period

If using Planzapin, patients should not breastfeed.

Drug interaction

olanzapin increases the effects on the nervous system of central neurotransmitter, including alcohol. Olanzapin may oppose the action of dopamin's ownership.

Neutral leukemia may be more common when olanzapin is used with Valproat.

There is a risk in theory of extending QT when using olanzapin combined with other drugs that have been known.

olanzapine metabolized through cytochrome P450 isoenzyme CYP1A2. The use of inhibitors, induction, or acting as a substrate of the enzyme above, which can affect plasma olinzapin concentrations and need to adjust the dose of planzapin. Fluvoxamine inhibits CYP1A2 inhibits the metabolism of olanzapine significantly. Cigarette smoke and carbamazepine increase the metabolism of planzapin.